Presentation is loading. Please wait.

Presentation is loading. Please wait.

Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens  Judith N. Müller, PhD, Markus Falk, PhD, Jatin Talwar, MSc, Nicole.

Published byLeon Stephens Modified over 5 years ago

Similar presentations

Presentation on theme: "Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens  Judith N. Müller, PhD, Markus Falk, PhD, Jatin Talwar, MSc, Nicole."— Presentation transcript:

1 Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens 
Judith N. Müller, PhD, Markus Falk, PhD, Jatin Talwar, MSc, Nicole Neemann, Erika Mariotti, PhD, Miriam Bertrand, MSci, Tobias Zacherle, PhD, Sotirios Lakis, MD, Roopika Menon, PhD, Christian Gloeckner, PhD, Markus Tiemann, MD, PhD, Lukas C. Heukamp, PhD, Roman K. Thomas, MD, Frank Griesinger, MD, Johannes M. Heuckmann, PhD  Journal of Thoracic Oncology  Volume 12, Issue 10, Pages (October 2017) DOI: /j.jtho Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 NEOplus and routine testing of tumor specimens show maximal concordance of driver mutations. (A) Patient cohort evaluated in this study. (B–D) ROS1 fusion in a patient with lung adenocarcinoma identified by routine testing and NEOplus. Adenocarcinoma of the lung of T1N2M0 stage IIIA was initially diagnosed in the male patient. After induction therapy with carboplatin and docetaxel, definitive chemoradiotherapy with cisplatin and vinorelbine was performed. Relapse in the right upper lobe with mediastinal lymph nodes was diagnosed, and a repeat biopsy was performed to permit routine testing and NEOplus molecular profiling. Fluorescence in situ hybridization staining identified a rearrangement in ROS1 with positive break-apart signals, as indicated by the arrow (B). The exact breakpoints in ezrin gene (EZR) and ROS1 were identified by NEOplus, as indicated by the Intregrative Genomics Viewer screenshot (C). Crizotinib treatment was started in July 2015, and the patient is currently in continuous partial remission (D). Arrows indicate tumor mass at time of treatment initiation. (E) Comparison of 75 tissue samples analyzed by routine testing and hybrid capture–based NEOplus, revealed a concordance, sensitivity, and specificity of 100%. NOS, not otherwise specified; CI, confidence interval. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 NEOliquid reveals a high concordance to routine tissue testing. (A) NEOliquid identifies a broad range of genomic alterations in tumor-associated genes. (B) The concordance of 82 liquid biopsies with the respective fresh frozen paraffin-embedded (FFPE) sample was 98%, with a sensitivity of 71% and a specificity of 100%. (C) The distribution of allele frequencies for point mutations and insertion/deletions (InDels) as identified in FFPE samples (left panel) and liquid biopsies (right panel) is shown. (D) Liquid biopsies are stratified by metastatic disease (at time of blood withdrawal) and plotted for the amount of cell-free DNA (cfDNA) (18 mL of whole blood, assay sensitivity, and specificity). For statistical evaluation a two-sided t test was applied. ***p Value lower than ID, identifier; TP53, tumor protein 53 gene; MET, MNNG HOS Transforming gene; ALK, ALK receptor tyrosine kinase gene; RET, ret proto-oncogene; ERBB2, erb-b2 receptor tyrosine kinase 2 gene; IDH1, isocitrate dehydrogenase (NADP(+)), 1 systolic gene; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene; CTNNB1, catenin beta 1; STK11, serine/threonine kinase 11 gene; KEAP1, kelch like ECH associated protein 1 gene; MAP2K1, mitogen-activated protein kinase kinase 1 gene; RB1, retinoblastoma 1 gene; CI, confidence interval; MAF, minor allele frequency. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 NEOliquid identifies actionable alterations that are not covered by routine testing. (A) Breakpoints of the kinesin family member 5B gene (KIF5B)–ret proto-oncogene (RET) translocation are visualized in the Intregrative Genomics Viewer. (B) Clinical response of a tumor harboring a KIF5B-RET translocation before and after treatment with cabozantinib. Arrows indicate tumor mass at time of treatment initiation. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens  Judith N. Müller, PhD, Markus Falk, PhD, Jatin Talwar, MSc, Nicole."

Similar presentations

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,
A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response.

A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response.
Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma  Qiushi Wang, Xin Yang, Yong He, Qiang Ma, Li Lin,

Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma  Qiushi Wang, Xin Yang, Yong He, Qiang Ma, Li Lin,
Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors  Alexa B. Schrock,

Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors  Alexa B. Schrock,
Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced.

Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced.
Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse  Karinna.

Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse  Karinna.
Detection of Rearrangements and Transcriptional Up-Regulation of ALK in FFPE Lung Cancer Specimens Using a Novel, Sensitive, Quantitative Reverse Transcription.

Detection of Rearrangements and Transcriptional Up-Regulation of ALK in FFPE Lung Cancer Specimens Using a Novel, Sensitive, Quantitative Reverse Transcription.
A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R 

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R 
Rafal Dziadziuszko, MD, PhD, Anh T

Rafal Dziadziuszko, MD, PhD, Anh T
MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values  Geun Dong Lee, MD, PhD, Seung Eun Lee, MD,

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values  Geun Dong Lee, MD, PhD, Seung Eun Lee, MD,
Adrian G. Sacher, MD, Kimberly M. Komatsubara, MD, Geoffrey R

Adrian G. Sacher, MD, Kimberly M. Komatsubara, MD, Geoffrey R
ERBB2-Mutated Metastatic Non–Small Cell Lung Cancer: Response and Resistance to Targeted Therapies  Jody C. Chuang, MD, PhD, Henning Stehr, PhD, Ying.

ERBB2-Mutated Metastatic Non–Small Cell Lung Cancer: Response and Resistance to Targeted Therapies  Jody C. Chuang, MD, PhD, Henning Stehr, PhD, Ying.
A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response.

A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response.
Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma  Shiyong Li, BS, Yoon-La Choi, MD, PhD, Zhuolin Gong, PhD, Xiao Liu, PhD,

Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma  Shiyong Li, BS, Yoon-La Choi, MD, PhD, Zhuolin Gong, PhD, Xiao Liu, PhD,
Recent Advances in Targeting ROS1 in Lung Cancer

Recent Advances in Targeting ROS1 in Lung Cancer
Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance.

Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance.
Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma  Nicolas Guibert,

Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma  Nicolas Guibert,
Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy  Deepa Rangachari, MD, Xiuning.

Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy  Deepa Rangachari, MD, Xiuning.
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,
Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M

Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M

Similar presentations

Ads by Google